← Eichor
Condition: Sars Cov 2 Acute Respiratory Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Sars Cov 2 Acute Respiratory Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Phase 1 · 1 location(s) · Stephanie B. Seminara, MD · NCT07224490
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05233605
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
Phase N/A · 1 location(s) · The Geneva Foundation · NCT06402318
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Phase 2 · 1 location(s) · Vanderbilt University Medical Center · NCT07189936
Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
NA · 1 location(s) · Fundación Cardioinfantil Instituto de Cardiología · NCT06871293
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
Phase N/A · 1 location(s) · Columbia University · NCT04448145
NC Testing in LC & POTS
NA · 1 location(s) · University of Calgary · NCT05914649
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
Phase N/A · 1 location(s) · VA Office of Research and Development · NCT06291870
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.